Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2023-08-18 Remuneration Information
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic ASA - Mandatory notification of trade by primary insider
Remuneration Information Classification · 99% confidence The document is titled "Navamedic ASA - Mandatory notification of trade by primary insider" and details the exercise of share options and subsequent subscription for new shares by key executives (CEO, CFO, CSO) on August 18, 2023. This activity involves transactions in the company's own shares by insiders. This directly aligns with the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by directors and executives (insider trades). Although it involves share issuance (SHA), the primary focus and mandatory notification requirement stem from the insider trading aspect.
2023-08-18 English
NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a 'Resolution to increase the share capital in connection with exercise of employee options'. It details the number of new shares issued (125,000), the resulting total share capital, and the mechanism (issuance of shares to settle exercised options). This directly relates to changes in the company's capital structure and share count, fitting the definition of 'Share Issue/Capital Change'. The code SHA is the most appropriate classification.
2023-08-18 English
Navamedic ASA: Significant growth across the business
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter and first half of 2023 (Q2 and H1 2023). It contains detailed financial statements, including profit and loss, balance sheet, and cash flow tables, as well as management's analysis of business performance, growth drivers, and M&A activity (Sensidose acquisition). It is not an earnings release (which would be a short summary) nor a report publication announcement (as it contains the full substantive financial data). Therefore, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-11 English
Navamedic ASA: Betydelig vekst på tvers av virksomheten
Investor Presentation Classification · 99% confidence The document text explicitly details 'Second quarter and first half year 2023 results' and presents comprehensive financial tables for Q2 2023, H1 2023, and comparative periods (Q2 2022, YTD 2022, FY 2022). It includes detailed sections on Revenue, Gross Margin, EBITDA, Balance Sheet, and Cash Flow. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year, specifically a half-year report. The presence of detailed financial statements and management commentary points away from a brief Earnings Release (ER) or a mere Report Publication Announcement (RPA). Since it covers the first half of the year comprehensively, the appropriate classification is Interim / Quarterly Report (IR).
2023-08-11 English
Navamedic ASA: Significant growth across the business
Interim / Quarterly Report Classification · 100% confidence The document is a 'Second quarter and half year results' report for Navamedic ASA. It contains detailed financial statements (income statement, cash flow, financial position), management commentary, and key performance indicators for the specified interim period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2023
2023-08-11 English
Navamedic ASA: Betydelig vekst på tvers av virksomheten
Interim / Quarterly Report Classification · 100% confidence The document is a 'Second quarter and half year results' report for Navamedic ASA. It contains detailed financial statements (income statement, cash flow, financial position), management commentary, and key performance indicators for the specified interim period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2023
2023-08-11 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.